Evidence map›Paper›PMID 33718490›Full record

ArticleERJ open research2021

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.

MeiLan K Han, Gerard J Criner, Mark T Dransfield, David M G Halpin, Christine E Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A Lipson, David A Lomas and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?American journal of respiratory and critical care medicine · 2025
    Review
  5. Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study.International journal of chronic obstructive pulmonary disease · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Future concepts in bronchodilation for COPD: dual-European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 3 countries.

MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Gerard J CrinerLewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Mark T DransfieldLung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
David M G HalpinMedical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Christine E JonesGSK, Research Triangle Park, NC, USA.
Sally KilbrideGSK, Uxbridge, UK.
Peter LangeSection of Epidemiology, Dept of Public Health, University of Copenhagen, Copenhagen, Denmark.
Sally LettisGSK, Uxbridge, UK.
David A LipsonGSK, Collegeville, PA, USA.ORCID https://orcid.org/0000-0001-6732-4593
David A LomasUCL Respiratory, University College London, London, UK.
Neil MartinGSK, Brentford, UK.
Fernando J MartinezNewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-8353-2349
Ian P NayaGSK, Brentford, UK.
Dave SinghCentre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Cornell University · USGlaxoSmithKline (United States) · USJohns Hopkins University · USManchester Academic Health Science Centre · GBResearch Triangle Park Foundation · USTemple University · USUniversity College London · GBUniversity of Alabama at Birmingham · USUniversity of Copenhagen · DKUniversity of Exeter · GBUniversity of Leicester · GBUniversity of Michigan · US

Funding

Medical Research Council MR/V034243/1
6 · The paper itself

Abstract

introductionClinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outcomes and the effect of single-inhaler triple

methodsIMPACT was a phase III, double-blind, 52-week, multicentre trial. Patients with symptomatic COPD and at least one moderate/severe exacerbation in the prior year were randomised 2:2:1 to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg. CID at the time-point of interest was defined as a moderate/severe exacerbation, ≥100 mL decrease in trough forced expiratory volume in 1 s or deterioration in health status (increase of ≥4.0 units in St George's Respiratory Questionnaire total score or increase of ≥2.0 units in COPD Assessment Test score) from baseline. A treatment-independent

resultsPatients with a CID by week 28 had significantly increased exacerbation rates after week 28, smaller improvements in lung function and health status at week 52 (all p<0.001), and increased risk of all-cause mortality after week 28

conclusionsPrevention of short-term disease worsening was associated with better long-term clinical outcomes. FF/UMEC/VI reduced CID risk

Identifiers

PMID33718490
PMCPMC7938047
OpenAlexW3127151169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.